Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis
- 9 November 2020
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 22 (11) , 828-834
Abstract
Background: Liraglutide was administered to patients with type 2 diabetes, and its effects on estimated glomerular filtration rate (eGFR) slopes and albuminuria were retrospectively evaluated. Methods: This study included 568 patients with type 2 diabetes who received liraglutide therapy (up to 0.9 mg/day) >1 year and were followed-up for a maximum of 2 years before and 7 years after treatment. The decline in renal function was estimated as the slope of the individual linear regression line of eGFR over the follow-up time. Spot urine samples were collected to measure albuminuria, which were calculated using creatinine levels. In addition, HbA1c, body weight, blood pressure, and heart rate were monitored. Results: The mean liraglutide treatment period was 3.1 ± 2.0 years. The mean baseline eGFR slope [mL/(min ·1.73 m 2 ·year)] was −2.75 ± 6.04. After liraglutide treatment, the mean eGFR slope significantly improved (−1.42 ± 4.30, P < 0.01). This effect appeared more pronounced for baseline eGFRs 2 ). Albuminuria, HbA1c, body weight, and systolic blood pressure levels were significantly reduced after treatment with liraglutide for 1 year, whereas diastolic blood pressure and heart rates were increased. Conclusions: Patients treated with liraglutide experienced a significantly slower annual decline in kidney function. The benefit appeared more pronounced in patients with the development and progression of diabetic kidney disease. These results suggest that the benefits of liraglutide on kidney function identified in clinical trials appear to be well generalizable to clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2014
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal AntibodyEndocrinology, 2014
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal diseaseKidney International, 2012
- Exenatide Exerts a Potent Antiinflammatory EffectThe Journal of Clinical Endocrinology & Metabolism, 2012
- Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohortsKidney International, 2011
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetesCurrent Medical Research and Opinion, 2010
- Heart Rate as a Risk Factor for Cardiovascular DiseaseProgress in Cardiovascular Diseases, 2009
- Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with InsulinEndocrine Practice, 2007
- Chronic Kidney Disease Predicts Cardiovascular DiseaseNew England Journal of Medicine, 2004